MT Newswires
NeoGenomics Says Natera Withdraws Appeal in Patent Case
📈
AI Sentiment
Highly Positive
8/10
- Home
- NTRA
NTRA
Natera Inc.
as of 12-15-2025 3:50pm EST
$229.09
$2.60
-1.12%
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Chart Type:
Time Range:
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 27.0B | IPO Year: | 2015 |
| Target Price: | $229.56 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $125.38 - $246.90 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,116,676,000 | Revenue Growth: | 38.17% |
| Revenue Growth (this year): | 32.77% | Revenue Growth (next year): | 16.51% |
AI-Powered NTRA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.97%
75.97%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Natera Inc. (NTRA)
Chapman Rowan E
Sell
Director
NTRA Dec 5, 2025
Avg Cost/Share
$243.23
Shares
4,366
Total Value
$1,061,389.14
Owned After
6,143
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Dec 1, 2025
Avg Cost/Share
$238.19
Shares
3,000
Total Value
$714,458.77
Owned After
111,312
Chapman Steven Leonard
Sell
CEO AND PRESIDENT
NTRA Dec 1, 2025
Avg Cost/Share
$238.20
Shares
4,400
Total Value
$1,047,501.95
Owned After
140,416
BOTHA ROELOF
Sell
Director
NTRA Nov 24, 2025
Avg Cost/Share
$234.43
Shares
75,000
Total Value
$17,708,935.58
Owned After
1,227,198
Sheena Jonathan
Sell
Director, Other
NTRA Nov 11, 2025
Avg Cost/Share
$208.03
Shares
1,500
Total Value
$311,933.77
Owned After
25,452
Sheena Jonathan
Sell
Director, Other
NTRA Nov 7, 2025
Avg Cost/Share
$194.12
Shares
3,070
Total Value
$591,159.28
Owned After
25,452
Rabinowitz Matthew
Sell
EXECUTIVE CHAIRMAN
NTRA Nov 4, 2025
Avg Cost/Share
$200.73
Shares
22,900
Total Value
$4,591,674.04
Owned After
2,280,852
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Nov 3, 2025
Avg Cost/Share
$198.96
Shares
3,000
Total Value
$595,810.04
Owned After
111,312
Rabinowitz Matthew
Sell
EXECUTIVE CHAIRMAN
NTRA Nov 3, 2025
Avg Cost/Share
$200.00
Shares
17,100
Total Value
$3,420,003.42
Owned After
2,280,852
SEC Form 4
Sheena Jonathan
Sell
Director, Other
NTRA Nov 3, 2025
Avg Cost/Share
$200.07
Shares
4,000
Total Value
$800,273.60
Owned After
25,452
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Chapman Rowan E | NTRA | Director | Dec 5, 2025 | Sell | $243.23 | 4,366 | $1,061,389.14 | 6,143 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Dec 1, 2025 | Sell | $238.19 | 3,000 | $714,458.77 | 111,312 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Dec 1, 2025 | Sell | $238.20 | 4,400 | $1,047,501.95 | 140,416 | |
| BOTHA ROELOF | NTRA | Director | Nov 24, 2025 | Sell | $234.43 | 75,000 | $17,708,935.58 | 1,227,198 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 11, 2025 | Sell | $208.03 | 1,500 | $311,933.77 | 25,452 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 7, 2025 | Sell | $194.12 | 3,070 | $591,159.28 | 25,452 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 4, 2025 | Sell | $200.73 | 22,900 | $4,591,674.04 | 2,280,852 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Nov 3, 2025 | Sell | $198.96 | 3,000 | $595,810.04 | 111,312 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 3, 2025 | Sell | $200.00 | 17,100 | $3,420,003.42 | 2,280,852 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 3, 2025 | Sell | $200.07 | 4,000 | $800,273.60 | 25,452 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Natera Collaborates With MEDSIR to Use Signatera Genome in Phase 2 Breast Cancer Trial
âž–
AI Sentiment
Neutral
5/10
Business Wire
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
📊
AI Sentiment
Positive
7/10
24/7 Wall St.
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
📈
AI Sentiment
Highly Positive
10/10
Simply Wall St.
Is It Too Late To Consider Natera After Its Recent 12.8% Price Surge?
📊
AI Sentiment
Positive
6/10
Business Wire
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
📈
AI Sentiment
Highly Positive
8/10
MedTech Dive
Natera acquires Foresight Diagnostics for up to $450M
📈
AI Sentiment
Highly Positive
8/10
Compare NTRA vs Leading Stocks
See how NTRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.